**Appendix Table E101. Results from studies assessing the ability of PFA-100 to predict bleeding events in patients with ischemic heart disease**

| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Malek, 200717295159Poland NR | Clopidogrel LD 300 or 600mg and maintaining 75mg daily | PFA-100 | Major bleeding  | Major bleeding  | Early cardiovascular events | Groups 1-3 | Major bleeding  | 0/29 (0) | OR=2.1(calculate)d | NR | p=0.71groups 1-3 vs. control Fisher’s exact test | NR | NR |  |
|  |  |  |  |  |  | Control  |  | 0/62 (0) |  |  |  |  |  |  |